DNA methylation of Hugl-2 is a prognostic biomarker in kidney renal clear cell carcinoma

DNA methylation of Hugl-2 is a prognostic biomarker in kidney renal clear cell carcinoma
复制标题

DOI:
10.1111/1440-1681.13390
复制
发表时间:
2020
期刊:
Clin Exp Pharmacol Physiol
影响因子:
--
通讯作者:
Peijun Liu
Peijun Liu
中科院分区:
--
文献类型:
--
作者:
Yi Miao;Fang Cao;Pingping Li;Peijun Liu

文献摘要

相似文献

It has been reported that loss of Hugl-2 contributes to tumour formation and progression.in vitro and in vivo. However, whether Hugl-2 levels decrease during kidney.renal clear cell carcinoma (KIRC) and the mechanism involved remain unknown. This.study aimed to investigate whether DNA methylation of Hugl-2 reduces its expression,.leading to the progression and poor prognosis of KIRC. Hugl-2 methylation and.mRNA expression and KIRC clinicopathological data were extracted from The Cancer.Genome Atlas (TCGA), and relationships among these factors were analyzed using.UALCAN, MethHC, Wanderer and LinkedOmics web tools. We found that Hugl-2.mRNA and protein levels were reduced in KIRC tissues. Moreover, Hugl-2 mRNA.levels were related to tumour grade and overall survival, and Hugl-2 methylation was.increased in KIRC. According to the results of methylation-specific PCR, KIRC cells.had higher Hugl-2 DNA methylation levels than HKC cells. Moreover, Hugl-2 DNA.methylation correlated negatively with Hugl-2 mRNA and was also related to the.pathology and T stage of KIRC patients. KIRC patients with high Hugl-2 DNA methylation.also had shorter overall survival. Additionally, methylation of cg08827674, a.Hugl-2 probe, was related to pathologic stage, T stage, neoplasm histologic grade,.serum calcium level without laterality, M stage, N stage, and ethnicity. Furthermore,.treatment with the DNA methylation inhibitor decitabine resulted in upregulation of.Hugl-2 mRNA and protein levels in KIRC cell lines. These results indicate that Hugl-2.DNA methylation may be both a prognostic marker and a therapeutic target in KIRC.